• News
  • SAN DIEGO
  • BioTech

Lpath reports interim results in cancer drug trial

Lpath Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has reported interim results in its Phase 2a trial investigating the drug Asonep as a treatment for metastatic renal cell carcinoma.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Lpath Inc.

Company Website

6335 Ferris Sq. Ste., A
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LPTN
2.91
  -0.05  
- 1.69%
22,730,000
5.30
2.75

Lpath Inc. Executive(s):

Scott Pancoast

  • Chief Executive Officer, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing
SIC - 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Subscribe Today!